Supplementary method Liquid chromatography/Tandem Mass Spectrometry analysis
The concentration of lapatinib in mouse plasma was determined by high-performance liquid chromatography (HPLC) with tandem mass spectrometry (LC-MS/MS) using validated methods. Plasma samples were extracted by protein precipitation using a solution of acetonitrile containing stable isotopically labeled letrozole-d4 (Sant Cruz) as an internal standard. After vortex-mixing for 3 minutes, the samples were centrifuged at approximately 14,000 rpm for 10 minutes. The extract was transferred into a 96 well plate for LC-MS/MS analysis by using an ultra-HPLC system (Agilent 1290) connected to a triple quadrupole tandem mass spectrometer (Agilent 6460) outfitted with an Agilent Jet Stream electrospray ionization source operating in the positive mode and multiple-reaction monitoring (MRM) detection with precursor product ion pairs of 581.2  365.2 for lapatinib, and 290.0  221.0 for the internal standard. Stock solution of letrozole-d4 was prepared in DMSO whereas lapatinib was prepared in methanol. Working stock solutions were diluted from the primary stock with dilution solution (methanol: water, 20:80, v: v) for fortification of the control plasma to prepare calibration standards. The calibration range was 10 to 10,000 ng/mL and was accomplished by weighted (1/concentration 2 ) linear regression of the ratio of the peak area of analyte to that of the added internal standard. All plasma samples were spiked with 10 μL of 500 ng/mL internal standard working solution. A reverse phase HPLC column was used for separation of the analyte. The analyte was eluted using a gradient of mobile phase A (1.0% formic acid in water) and mobile phase B (1.0% formic acid in methanol) from 35% to 95% mobile phase B.
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